Literature DB >> 21660565

The use of cost per life year gained as a measurement of cost-effectiveness in Spain: a systematic review of recent publications.

José Manuel Rodríguez Barrios1, Ferran Pérez Alcántara, Carlos Crespo Palomo, Paloma González García, Enrique Antón De Las Heras, Max Brosa Riestra.   

Abstract

OBJECTIVES: The objective of this study was to evaluate the methodological characteristics of cost-effectiveness evaluations carried out in Spain, since 1990, which include LYG as an outcome to measure the incremental cost-effectiveness ratio.
METHODS: A systematic review of published studies was conducted describing their characteristics and methodological quality. We analyse the cost per LYG results in relation with a commonly accepted Spanish cost-effectiveness threshold and the possible relation with the cost per quality adjusted life year (QALY) gained when they both were calculated for the same economic evaluation.
RESULTS: A total of 62 economic evaluations fulfilled the selection criteria, 24 of them including the cost per QALY gained result as well. The methodological quality of the studies was good (55%) or very good (26%). A total of 124 cost per LYG results were obtained with a mean ratio of 49,529<euro> and a median of 11,490<euro> (standard deviation of 183,080). Since 2003, a commonly accepted Spanish threshold has been referenced by 66% of studies. A significant correlation was found between the cost per LYG and cost per QALY gained results (0.89 Spearman-Rho, 0.91 Pearson).
CONCLUSIONS: There is an increasing interest for economic health care evaluations in Spain, and the quality of the studies is also improving. Although a commonly accepted threshold exists, further information is needed for decision-making as well as to identify the relationship between the costs per LYG and per QALY gained.

Entities:  

Mesh:

Year:  2011        PMID: 21660565     DOI: 10.1007/s10198-011-0326-y

Source DB:  PubMed          Journal:  Eur J Health Econ        ISSN: 1618-7598


  57 in total

Review 1.  Twenty years of health care economic analysis in Spain: are we doing well?

Authors:  A García-Altés
Journal:  Health Econ       Date:  2001-12       Impact factor: 3.046

2.  Cost-effectiveness of dietary treatment of hypercholesterolemia in Spain.

Authors:  P P Rubió
Journal:  Public Health       Date:  1997-01       Impact factor: 2.427

Review 3.  The use of quality-adjusted life-years in the economic evaluation of health technologies in Spain: a review of the 1990-2009 literature.

Authors:  José Manuel Rodriguez; Silvia Paz; Luis Lizan; Paloma Gonzalez
Journal:  Value Health       Date:  2011-06       Impact factor: 5.725

4.  Pharmacoeconomic analysis of adjuvant therapy with exemestane, anastrozole, letrozole or tamoxifen in postmenopausal women with operable and estrogen receptor-positive breast cancer.

Authors:  J M Gil; C Rubio-Terrés; A Del Castillo; P González; F Canorea
Journal:  Clin Transl Oncol       Date:  2006-05       Impact factor: 3.405

5.  Cost effectiveness of adjuvant therapy for hepatocellular carcinoma during the waiting list for liver transplantation.

Authors:  J M Llovet; X Mas; J J Aponte; J Fuster; M Navasa; E Christensen; J Rodés; J Bruix
Journal:  Gut       Date:  2002-01       Impact factor: 23.059

6.  A cost-effectiveness analysis of peginterferon alfa-2b plus ribavirin for the treatment of naive patients with chronic hepatitis C.

Authors:  M Buti; M Medina; M A Casado; J B Wong; L Fosbrook; R Esteban
Journal:  Aliment Pharmacol Ther       Date:  2003-03-01       Impact factor: 8.171

7.  [Rituximab cost analysis for maintenance treatment of patients with follicular lymphoma].

Authors: 
Journal:  Farm Hosp       Date:  2008 Jan-Feb

8.  Cost-effectiveness of cardiovascular prevention programs in Spain.

Authors:  P Plans-Rubió
Journal:  Int J Technol Assess Health Care       Date:  1998       Impact factor: 2.188

9.  [The cost-effectiveness of pneumococcal vaccination in Catalonia].

Authors:  P Plans Rubió; P Garrido Morales; L Salleras Sanmartí
Journal:  Rev Esp Salud Publica       Date:  1995 Sep-Oct

10.  Cost-effectiveness analysis of sunitinib in patients with metastatic and/or unresectable gastrointestinal stroma tumours (GIST) after progression or intolerance with imatinib.

Authors:  Luis Paz-Ares; Xavier García del Muro; Enrique Grande; Paloma González; M Brosa; Silvia Díaz
Journal:  Clin Transl Oncol       Date:  2008-12       Impact factor: 3.405

View more
  8 in total

Review 1.  Analysis of economic evaluations of pharmacological cancer treatments in Spain between 1990 and 2010.

Authors:  Angel Sanz-Granda; Alvaro Hidalgo; Juan E del Llano; Joan Rovira
Journal:  Clin Transl Oncol       Date:  2012-11-21       Impact factor: 3.405

2.  Comparative efficiency research (COMER): meta-analysis of cost-effectiveness studies.

Authors:  Carlos Crespo; Antonio Monleon; Walter Díaz; Martín Ríos
Journal:  BMC Med Res Methodol       Date:  2014-12-22       Impact factor: 4.615

Review 3.  Treatment options for progression or recurrence of glioblastoma: a network meta-analysis.

Authors:  Catherine McBain; Theresa A Lawrie; Ewelina Rogozińska; Ashleigh Kernohan; Tomos Robinson; Sarah Jefferies
Journal:  Cochrane Database Syst Rev       Date:  2021-05-04

4.  Choice of Fluids in Severe Septic Patients - A Cost-effectiveness Analysis Informed by Recent Clinical Trials.

Authors:  Albert Farrugia; Megha Bansal; Sonia Balboni; Mary Clare Kimber; Gregory S Martin; Josephine Cassar
Journal:  Rev Recent Clin Trials       Date:  2014

5.  Cost-utility analysis of certolizumab pegol versus alternative tumour necrosis factor inhibitors available for the treatment of moderate-to-severe active rheumatoid arthritis in Spain.

Authors:  Renata Villoro; Juan Antonio Blasco; Pablo Talavera; Belén Ferro; Oana Purcaru; Álvaro Hidalgo-Vega
Journal:  Cost Eff Resour Alloc       Date:  2015-06-09

6.  Cost-utility analysis of Palivizumab for Respiratory Syncytial Virus infection prophylaxis in preterm infants: update based on the clinical evidence in Spain.

Authors:  M Sanchez-Luna; R Burgos-Pol; I Oyagüez; J Figueras-Aloy; M Sánchez-Solís; F Martinón-Torres; X Carbonell-Estrany
Journal:  BMC Infect Dis       Date:  2017-10-17       Impact factor: 3.090

Review 7.  The quality of reporting methods and results of cost-effectiveness analyses in Spain: a methodological systematic review.

Authors:  Ferrán Catalá-López; Manuel Ridao; Adolfo Alonso-Arroyo; Anna García-Altés; Chris Cameron; Diana González-Bermejo; Rafael Aleixandre-Benavent; Enrique Bernal-Delgado; Salvador Peiró; Rafael Tabarés-Seisdedos; Brian Hutton
Journal:  Syst Rev       Date:  2016-01-07

Review 8.  Public health impact and cost-effectiveness of dairy products supplemented with vitamin D in prevention of osteoporotic fractures.

Authors:  Olivier Ethgen; Mickaël Hiligsmann; Nansa Burlet; Jean-Yves Reginster
Journal:  Arch Public Health       Date:  2015-12-14
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.